What compounds target HLA-B?

BiohacksAI has identified 35 compounds that interact with HLA-B (major histocompatibility complex, class I, B). Top compounds include: Camptothecin, Ouabain, withaferin, celastrol, Disulfiram. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is HLA-B (major histocompatibility complex,)?

HLA-B is major histocompatibility complex, class I, B. It is a molecular target for 35 compounds documented in PubMed bioassay data. NCBI Gene ID: 3106.

HLA-B

MOLECULAR TARGET

major histocompatibility complex, class I, B

NCBI Gene: 310635 compounds

HLA-B (major histocompatibility complex, class I, B) is targeted by 35 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting HLA-B

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	Camptothecin	1.79	5
2	Ouabain	1.61	4
3	withaferin	1.61	4
4	celastrol	1.39	3
5	Disulfiram	1.39	3
6	Idarubicin	1.39	3
7	Azacitidine	1.10	2
8	Azacitidine	1.10	2
9	Bortezomib	1.10	2
10	Calcimycin	1.10	2
11	Crizotinib	1.10	2
12	cycloheximide	1.10	2
13	Dactinomycin	1.10	2
14	Daunorubicin	1.10	2
15	Emetine	1.10	2
16	Epirubicin	1.10	2
17	Homoharringtonine Semisynthetic derivative of harringtonine that acts as	1.10	2
18	3-(1-(3-hydroxy-4-methoxyphenyl)methylidene)-6-methylchroman-4-one [Supplementary Concept]	1.10	2
19	kenpaullone	1.10	2
20	Proscillaridin	1.10	2
21	trichostatic acid [Supplementary Concept] related to trichostatin	1.10	2
22	Tripterygium	1.10	2
23	cbd	0.69	1
24	Genistein	0.69	1
25	Sertraline	0.69	1
26	cannabidiol	0.69	1
27	Deslanoside Deacetyllanatoside C.	0.69	1
28	Digitoxin	0.69	1
29	Digoxin	0.69	1
30	Feprazone	0.69	1
31	Leflunomide	0.69	1
32	Nitrendipine	0.69	1
33	Phenylbutazone	0.69	1
34	triolimus [Supplementary Concept]	0.69	1
35	Thapsigargin	0.69	1

About HLA-B as a Drug Target

HLA-B (major histocompatibility complex, class I, B) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 35 compounds with documented HLA-B interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

HLA-B inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.